URGN
UroGen Pharma Ltd. · Healthcare · Market cap $1.2B
Insiders sold $3.0M net in the last 90 days ·3 sellers, 0 buyers· latest Form 4 filed Oct 9, 2026
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$4.8M
reported sales (SEC code S)
Unique Insiders
3
in the rolling window
Latest filing
Oct 9, 2026
Degnan Chris
UroGen Pharma Ltd. (URGN) has 20 SEC Form 4 filings (33 transaction rows) in the rolling window, disclosed by 3 distinct insiders. Most recent filing: Oct 9, 2026.
Inside the rolling window, 3 insiders at UroGen Pharma Ltd. reported no open-market purchases and 11 open-market sales totaling $4.8M. The most active filer is Chief Medical Officer Schoenberg Mark with 8 filings. Insiders have net sold $4.2M over the trailing 6 months. The most recent open-market filing is a sale of 2,202 shares by Chief Financial Officer Degnan Chris, dated Oct 8, 2026, worth $81K.
- Industry:Biotechnology
- CEO:Elizabeth Barrett
- Employees:300
- HQ:Princeton, NJ, US
- IPO:2017-05-04
| Source | |||||||
|---|---|---|---|---|---|---|---|
Degnan ChrisFirst filing | Chief Financial Officer | Sale | 2,202 | $81K | Oct 9 | -32.8% | SEC ↗ |
| Chief Medical Officer | Sale | 871 | $37K | Sep 9 | -45.0% | SEC ↗ | |
Smith Jason DrewFirst in 7 months | General Counsel | Sale | 1,519 | $65K | Sep 9 | -45.0% | SEC ↗ |
| Chief Medical Officer | Sale | 60,677 | $2.9M | Aug 24 | -46.4% | SEC ↗ | |
| Chief Medical Officer | Sale | 10,000 | $400K | Jul 10 | -35.8% | SEC ↗ | |
| Chief Medical Officer | Sale | 10,000 | $350K | Jun 24 | -30.1% | SEC ↗ | |
| Chief Medical Officer | Sale | 5,222 | $143K | Jun 9 | -12.2% | SEC ↗ | |
Schoenberg MarkFirst in 3 months | Chief Medical Officer | Sale | 10,000 | $300K | May 11 | -21.0% | SEC ↗ |
Smith Jason DrewFirst filing | General Counsel | Sale | 7,479 | $147K | Feb 11 | +17.1% | SEC ↗ |
| Chief Medical Officer | Sale | 7,373 | $145K | Feb 4 | — | SEC ↗ | |
Schoenberg MarkFirst filing | Chief Medical Officer | Sale | 10,000 | $250K | Nov 20 | — | SEC ↗ |
Earnings: last 7 quarters
Frequently asked questions
How many SEC Form 4 insider filings does URGN have?
UroGen Pharma Ltd. (URGN) has 20 SEC Form 4 filings (33 transaction rows) in the rolling 365-day window, disclosed by 3 distinct insiders. Most recent filing: Oct 9, 2026.
When was the most recent SEC Form 4 filing for URGN?
The most recent Form 4 filing for URGN on Tracefour is dated Oct 9, 2026.
Who is the most active insider at URGN?
The most active SEC Form 4 filer at URGN in the rolling window is Chief Medical Officer Schoenberg Mark, with 8 filings.
What is the net insider flow at URGN over the last 6 months?
Over the trailing 180 days, insiders at URGN have net sold $4.2M based on SEC Form 4 disclosures.
What is the total insider buy and sell value at URGN in the current window?
Inside the rolling window, insiders at URGN bought $0 and sold $4.8M based on SEC Form 4 filings.
Can I get alerts for URGN insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at UroGen Pharma Ltd. (URGN). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
UroGen Pharma Ltd. is in the Healthcare sector.